Trial · NCT01940887

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

NCT01940887, Phase 3, Terminated, Ophthotech Corporation; results first posted 2020-09-30

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy. Trials, record NCT01940887. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01940887

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
NCT number: NCT01940887
Status: Terminated
Phases: Phase 3
Enrollment: 645 participants, actual
Lead sponsor: Ophthotech Corporation
Conditions: Age-Related Macular Degeneration
Interventions: E10030, bevacizumab or aflibercept, E10030 sham injection
First posted: 2013-09-12
Last updated: 2024-10-31
Results first posted: 2020-09-30

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Mean Change in Visual Acuity (Measured at Baseline and at the Month 12 Visit)	12 months	The primary efficacy endpoint is the mean change in visual acuity (ETDRS letters) measured at baseline and at the month 12 visit. Higher ETDRS letters represents higher vision and a higher change in ETDRS letters represents better functioning.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Mean Change in Visual Acuity (Measured at Baseline and at the Month 12 Visit)	12 months	As pre-specified in the SAP and per the study design, 2 treatment groups (E10030 +Eylea/Avastin vs. Sham + Eylea/Avastin) will be compared. All 642 subjects who received at least one dose of the study drug, irrespective of the dose received, were included in the analysis.	letters	MEAN

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Mean Change in Visual Acuity (Measured at Baseline and at the Month 12 Visit)	E10030 + Bevacizumab or Aflibercept		9.42	Standard Error 0.85	letters
Mean Change in Visual Acuity (Measured at Baseline and at the Month 12 Visit)	Sham + Bevacizumab or Aflibercept		9.04	Standard Error 0.85	letters

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Year 1	STARTED	E10030 + Bevacizumab or Aflibercept	322
Year 1	STARTED	Sham + Bevacizumab or Aflibercept	320
Year 1	COMPLETED	E10030 + Bevacizumab or Aflibercept	283
Year 1	COMPLETED	Sham + Bevacizumab or Aflibercept	297
Year 1	NOT COMPLETED	E10030 + Bevacizumab or Aflibercept	39
Year 1	NOT COMPLETED	Sham + Bevacizumab or Aflibercept	23
Year 2	STARTED	E10030 + Bevacizumab or Aflibercept	283
Year 2	STARTED	Sham + Bevacizumab or Aflibercept	297
Year 2	COMPLETED	E10030 + Bevacizumab or Aflibercept	66
Year 2	COMPLETED	Sham + Bevacizumab or Aflibercept	75

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events202

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Intraocular pressure increased	Investigations	E10030 + Bevacizumab or Aflibercept	22	322	46
other	Intraocular pressure increased	Investigations	Sham + Bevacizumab or Aflibercept	20	320	35
other	Conjunctival haemorrhage	Eye disorders	E10030 + Bevacizumab or Aflibercept	39	322	85
other	Conjunctival haemorrhage	Eye disorders	Sham + Bevacizumab or Aflibercept	31	320	48
other	Punctate keratitis	Eye disorders	E10030 + Bevacizumab or Aflibercept	21	322	34
other	Punctate keratitis	Eye disorders	Sham + Bevacizumab or Aflibercept	14	320	39
other	Eye pain	Eye disorders	E10030 + Bevacizumab or Aflibercept	18	322	26
other	Eye pain	Eye disorders	Sham + Bevacizumab or Aflibercept	21	320	35
other	Vitreous detachment	Eye disorders	E10030 + Bevacizumab or Aflibercept	20	322	21
other	Vitreous detachment	Eye disorders	Sham + Bevacizumab or Aflibercept	19	320	23

1 to 10 of 202Source ClinicalTrials.gov

See all 202 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	E10030 + Bevacizumab or Aflibercept	7	322
Total, all-cause mortality	Sham + Bevacizumab or Aflibercept	6	320
Total, other adverse events	E10030 + Bevacizumab or Aflibercept	105	322
Total, other adverse events	Sham + Bevacizumab or Aflibercept	107	320
Total, serious adverse events	E10030 + Bevacizumab or Aflibercept	58	322
Total, serious adverse events	Sham + Bevacizumab or Aflibercept	32	320

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
30957581	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
E10030 + Bevacizumab or Aflibercept vs Sham + Bevacizumab or Aflibercept: deaths from any cause	Trial comparisons
E10030 + Bevacizumab or Aflibercept vs Sham + Bevacizumab or Aflibercept: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01940887

GET https://conductscience.org/api/trials/v1/NCT01940887/events?page=2

API reference For AI assistants